About this Watch
Day two will make the case for why C-peptide should be considered as a primary endpoint for trials in new-onset T1D. We will review the evidence that links C-peptide to clinical benefits and its correlation with improvements in HbA1c. Updated analyses of the TOMI database of new-onset clinical trials will be presented and discussed. We will then shift to a focus on how a C-peptide endpoint could enable and accelerate the development of novel therapies, the impact on clinical trial design and conduct, and the context of use that could apply. The second day will end with a comprehensive panel discussion with a focus on achieving clarity and identifying actionable next steps.
Day Two: Where We Want to Go with Trials in New-Onset T1D / 18 June 2025
Stage Schedule
Day Two: Welcome and Introduction
Joseph Hedrick
Executive Director, Type 1 Diabetes Consortium, Critical Path Institute
Session Three: C-Peptide and Clinical Benefits in T1D
Prof. Helen Colhoun, Prof. Colin Mark Dayan & Kimberly Collins
Session Four: How Can C-Peptide Be Used to Accelerate Drug Development in New-Onset T1D?
Joseph Hedrick
Executive Director, Type 1 Diabetes Consortium, Critical Path Institute
Session Three-Four Panel Discussion: C-Peptide as Biomarker in Trials of T1D
Prof. Helen Colhoun, Stephen Karpen, Joseph Hedrick, Prof. Colin Mark Dayan, Kimberly Collins, Christoph Tasto & Justin Penzenstadler, PharmD
Panel Discussion: The Big Picture, Where Do We Stand and What's Next?
Matthias von Herrath, Stephen Karpen, Jeffrey Siegel, Elisabeth Niemoeller, John Sharretts, MD & Jason Gaglia, MD, MMSc
